BeyondSpring Pharmaceuticals is developing Plinabulin, a first‑in‑class small‑molecule immune modulator that activates GEF‑H1 and reversibly binds tubulin to promote dendritic cell maturation and robust T‑cell priming. Clinical data across multiple solid‑tumor indications, including NSCLC, show improved overall survival, reduced chemotherapy‑induced neutropenia, and high disease‑control rates when combined with radiation or PD‑1/PD‑L1 inhibitors. The company targets oncology developers seeking a novel agent to enhance combination regimens and deliver a more balanced efficacy‑safety profile for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with various cancers often experience limited treatment options that provide modest survival benefits while causing significant side effects such as chemotherapy‑induced neutropenia, reducing quality of life and limiting the ability to combine therapies.
Solution
BeyondSpring Pharmaceuticals is developing Plinabulin, a first‑in‑class small‑molecule immune modulator that activates GEF‑H1 and binds reversibly to tubulin to promote dendritic cell maturation and robust T‑cell priming. This novel mechanism aims to enhance anti‑tumor immunity while delivering a more balanced efficacy‑safety profile compared with conventional chemotherapy. Clinical data across multiple tumor types, including non‑small cell lung cancer, show improved overall survival, reduced neutropenia, and high disease‑control rates when combined with radiation or PD‑1/PD‑L1 inhibitors. The company positions Plinabulin as a “patient‑first” therapy intended to extend survival and improve quality of life, potentially becoming a practice‑changing option in oncology.
Target Audience
Primary customers are oncology pharmaceutical developers and clinical trial sponsors seeking to incorporate a novel immune‑modulating agent into combination regimens for solid‑tumor indications.
Features
- Small‑molecule agent that activates GEF‑H1 and reversibly binds tubulin to trigger dendritic cell maturation
- Demonstrated reduction of chemotherapy‑induced neutropenia across six clinical studies
- Combination potential with radiation therapy and PD‑1/PD‑L1 checkpoint inhibitors, achieving >50% disease‑control rates in resistant cancers
- Clinical evaluation in over 12 studies from Phase 1 to Phase 3, involving more than 700 treated cancer patients
- Evidence of overall survival benefit in EGFR‑wild‑type NSCLC, including improved outcomes in Asian subpopulations